Colorectal cancer patients with mismatch repair-deficient, but not MMR-proficient tend to benefit from immune checkpoint blockade therapy. Here, the authors identify interactions among tumor and immune cells that are associated with the responsiveness to immunotherapy in colorectal cancer.
- Yu Feng
- Wenjuan Ma
- Rongxin Zhang
